Abstract:We read with interest the article by Merola et al.1Merola J.F. Tian H. Patil D. et al.Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States.J Am Acad Dermatol. 2022; 86: 748-757Abstract Full Text Full Text PDF PubMed Scopus (8) Google Scholar The authors used treatment classes for psoriasis as surrogates for disease severity and explored the incidence of psoriatic arthritis (PsA) among patients with psoriasis receiving different treatments. The highest incidence of PsA was observed among the patients with psoriasis treated with biologics. This finding seems unreasonable because the biologics approved for psoriasis are also effective for PsA rather than facilitating the onset of PsA. We have the following concerns that are worthy of being addressed. First, the methodology is not appropriate to use treatment classes of nonsystemics, nonbiologic systemic therapies, and biologics as surrogates for mild, moderate, and severe psoriasis. Treatment classes are not parallel with psoriasis severity in practice. The choice of biologics for psoriasis is related to not only the severity of the disease but also other reasons in clinical practice, such as skin involvement of sensitive areas such as genitalia or face or subjective willingness from patients. Additionally, in the United States, the decision to use biologics involves consideration of insurance coverage and medication costs. Conversely, the reason for prescribing nonbiologics is not necessarily limited to milder psoriasis but also because of comorbidities or safety concerns. Second, the diagnosis of PsA by the International Classification of Diseases code is not accurate because PsA is often miscoded in databases. The positive predictive value to diagnose PsA by International Classification of Diseases code was reported to be 69%.2Wallman J.K. Alenius G.M. Klingberg E. et al.Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register.Scand J Rheumatol. Published online June 6, 2022; https://doi.org/10.1080/03009742.2022.2066807Crossref Scopus (4) Google Scholar The accurate diagnosis of PsA among patients with psoriasis is challenging. Musculoskeletal symptoms in patients with psoriasis can also be caused by conditions other than PsA, such as osteoarthritis or gout. Discrimination between causes of musculoskeletal pain and PsA is difficult, especially for dermatologists. It is reported that more than half of patients with psoriasis who were diagnosed with PsA from dermatology were given a revised diagnosis after attending the rheumatology clinics.3Lubrano E. Delle Sedie A. Romanelli M. et al.Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study.Clin Rheumatol. 2021; 40: 2251-2262Crossref PubMed Scopus (7) Google Scholar Among patients with psoriasis complaining of joint pain, only 33.0% of them were found to have a confirmed diagnosis of PsA.3Lubrano E. Delle Sedie A. Romanelli M. et al.Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study.Clin Rheumatol. 2021; 40: 2251-2262Crossref PubMed Scopus (7) Google Scholar Additionally, underdiagnosis of PsA is very common. It is reported that dermatologists rarely code for arthritis and musculoskeletal issues in patients with psoriasis.4Ogdie A. Rozycki M. Arndt T. Shi C. Kim N. Hur P. Longitudinal analysis of the patient pathways to diagnosis of psoriatic arthritis.Arthritis Res Ther. 2021; 23: 252Crossref PubMed Scopus (6) Google Scholar Moreover, dermatologists may add an International Classification of Diseases code for PsA to enhance the ability to get insurance coverage for the biologic based on the reimbursement policy. This might be one of the explanations for the spike in PsA incidence within the first year after the initiation of biologic treatment. Third, in several studies, it has been observed that biologic treatment for psoriasis reduced the risk of PsA development.5Rosenthal Y.S. Schwartz N. Sagy I. Pavlovsky L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study.Arthritis Rheumatol. 2022; 74: 237-243Crossref PubMed Scopus (16) Google Scholar Although the authors of this study observed that the incidence of PsA is higher among patients with psoriasis treated with biologic agents than in those treated with nonbiologics, the implication that biologics may promote PsA is without adequate foundation. The defect of methodology and confounding factors, mainly selection bias, may have contributed to these results. The patients were selected from electronic health record data but not the general population and were grouped according to their therapies. Therefore, factors such as differential prescribing patterns and reimbursement policy practices between biologic and nonbiologic treatments could affect patient selection and lead to selection bias. None disclosed.

Does biologic therapy impact the development of PsA among patients with psoriasis?

Biologic Treatment for Psoriasis is Unlikely to Facilitate Psoriatic Arthritis Development

Risk of Developing Inflammatory Arthritis in Psoriasis Patients Initiating Treatment With Biologics: A Population Based Analysis

Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development

Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry

Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities

P072 Risk of incident cancer, excluding keratinocyte carcinoma, in patients with psoriasis treated with biologic therapy: a prospective cohort study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), on behalf of the BADBIR Study Group

Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS)

O05 Risk of keratinocyte carcinomas in patients with psoriasis treated with biologic therapy: analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), on behalf of the BADBIR Study Group

Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study

Biologic Treatment of Psoriasis and Tuberculosis Testing: A Retrospective Analysis

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis

Long-Term Outcomes of Patients with Biologically Treated Psoriatic Arthritis and Atopic Dermatitis—A Single-Center Experience

Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study

Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis

Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review

The impacts of biologic treatment on metabolic profiling in psoriasis

Higher Synovial Immunohistochemistry Reactivity of IL-17A, Dkk1, and TGF-β1 in Patients with Early Psoriatic Arthritis and Rheumatoid Arthritis Could Predict the Use of Biologics

Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis

Characteristics of Patients With Psoriasis Treated With Various Biologics - A Danish Cohort Study

Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study